These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17508936)

  • 21. Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods.
    Wei Y; Li J; Chen Z; Wang F; Huang W; Hong Z; Lin J
    Eur J Med Chem; 2015 Aug; 101():409-18. PubMed ID: 26185005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
    Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
    J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Empirical free energy as a target function in docking and design: application to HIV-1 protease inhibitors.
    King BL; Vajda S; DeLisi C
    FEBS Lett; 1996 Apr; 384(1):87-91. PubMed ID: 8797810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
    Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
    Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QXP: powerful, rapid computer algorithms for structure-based drug design.
    McMartin C; Bohacek RS
    J Comput Aided Mol Des; 1997 Jul; 11(4):333-44. PubMed ID: 9334900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries.
    Chang MW; Lindstrom W; Olson AJ; Belew RK
    J Chem Inf Model; 2007; 47(3):1258-62. PubMed ID: 17447753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction.
    Brylinski M
    J Chem Inf Model; 2013 Nov; 53(11):3097-112. PubMed ID: 24171431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the conformational landscapes of HIV protease structural ensembles using principal component analysis.
    Hassan S; Srikakulam SK; Chandramohan Y; Thangam M; Muthukumar S; Gayathri Devi PK; Hanna LE
    Proteins; 2018 Sep; 86(9):990-1000. PubMed ID: 30051500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parallel screening and activity profiling with HIV protease inhibitor pharmacophore models.
    Steindl TM; Schuster D; Laggner C; Chuang K; Hoffmann RD; Langer T
    J Chem Inf Model; 2007; 47(2):563-71. PubMed ID: 17381173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina.
    Chang MW; Ayeni C; Breuer S; Torbett BE
    PLoS One; 2010 Aug; 5(8):e11955. PubMed ID: 20694138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease.
    Li N; Ainsworth RI; Ding B; Hou T; Wang W
    J Chem Inf Model; 2015 Jul; 55(7):1400-12. PubMed ID: 25993532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Algorithm to design inhibitors using stereochemically mixed l,d polypeptides: Validation against HIV protease.
    Gupta P; Durani S
    Int J Biol Macromol; 2015 Nov; 81():410-7. PubMed ID: 26279121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probing structure-function relationships in human immunodeficiency virus type 1 protease via molecular dynamics simulation.
    Harte WE; Beveridge DL
    Methods Enzymol; 1994; 241():178-95. PubMed ID: 7854178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methods for the prediction of protein-ligand binding sites for structure-based drug design and virtual ligand screening.
    Laurie AT; Jackson RM
    Curr Protein Pept Sci; 2006 Oct; 7(5):395-406. PubMed ID: 17073692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular dynamics-based virtual screening: accelerating the drug discovery process by high-performance computing.
    Ge H; Wang Y; Li C; Chen N; Xie Y; Xu M; He Y; Gu X; Wu R; Gu Q; Zeng L; Xu J
    J Chem Inf Model; 2013 Oct; 53(10):2757-64. PubMed ID: 24001302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A semiempirical free energy force field with charge-based desolvation.
    Huey R; Morris GM; Olson AJ; Goodsell DS
    J Comput Chem; 2007 Apr; 28(6):1145-52. PubMed ID: 17274016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
    Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.
    Shenderovich MD; Kagan RM; Heseltine PN; Ramnarayan K
    Protein Sci; 2003 Aug; 12(8):1706-18. PubMed ID: 12876320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.